PT2977
Modify Date: 2024-01-08 18:13:08
PT2977 structure
|
Common Name | PT2977 | ||
|---|---|---|---|---|
| CAS Number | 1672668-24-4 | Molecular Weight | 383.34 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C17H12F3NO4S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of PT2977PT2977 is an orally active and selective HIF-2α inhibitor with an IC50 of 9 nM. PT2977, as a second-generation HIF-2α inhibitor, increases potency and improves pharmacokinetic profile. PT2977 is a potential treatment for Clear cell renal cell carcinoma (ccRCC) and von Hippel–Lindau (VHL) disease[1]. |
| Name | PT2977 |
|---|
| Description | PT2977 is an orally active and selective HIF-2α inhibitor with an IC50 of 9 nM. PT2977, as a second-generation HIF-2α inhibitor, increases potency and improves pharmacokinetic profile. PT2977 is a potential treatment for Clear cell renal cell carcinoma (ccRCC) and von Hippel–Lindau (VHL) disease[1]. |
|---|---|
| Related Catalog | |
| Target |
HIF-2α:9 nM (IC50) |
| In Vitro | PT2977 potently and dose-dependently reduces mRNA levels of human cyclin D1, a target gene regulated by HIF-2α, and leads to rapid and dose-dependent reduction in EPO expression[1]. |
| References |
| Molecular Formula | C17H12F3NO4S |
|---|---|
| Molecular Weight | 383.34 |